Latest news for Universal Ibogaine (OTC:IBOGF) Stock

Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

cristian-escobar-abkEAOjnY0s-unsplash

Biotech

Cannabis

Psychedelics

Financing

Legal

Management

Global

BWVI

CMPS

IBOGF

Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds &amp; More

UNIVERSAL IBOGAINE INC by Universal Ibogaine Inc.

Universal Ibogaine Inc

News

Meiwu Technology Regains Compliance With Nasdaq Listing Rule, Which Requires Ordinary Shares To Maintain Minimum Bid Price

Shares of&nbsp;MicroStrategy Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) dropped by 4.08% following the company&#8217;s announcement to issue more shares to finance additional Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) acquisitions. This move aligns with MicroStrategy&#8217;s ongoing strategy to bolster its Bitcoin reserves.
What Happened: MicroStrategy&#8217;s recent filing&nbsp;with the U.S. Securities and&nbsp;Exchange Commission (SEC) aims to expand&nbsp;the authorized number of Class&nbsp;A&nbsp;common stock from 330 million&nbsp;to 10.33 billion units and&nbsp;preferred stock from 5 million&nbsp;to over 1 billion units.&nbsp;This move underscores the company&#8217;s transition from a software enterprise&nbsp;to a major Bitcoin investor.
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/24/12/42664692/bitcoin-flat-ethereum-dogecoin-spike-ahead-of-christmas-analyst-says-decline-in-btc-dominance-leaves-room-for-altcoins-to-pick-up?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Flat, Ethereum, Dogecoin Spike Ahead Of Christmas: Analyst Says Decline In BTC Dominance Leaves &#8216;Room For Altcoins To Pick Up&#8217;</a>
The company recently acquired&nbsp;$561 million worth of Bitcoin,&nbsp;marking its seventh consecutive week&nbsp;of purchases, with total holdings now estimated at $40 billion. Despite Bitcoin&#8217;s 135% increase this year, market volatility is expected as $43 billion in&nbsp;Bitcoin and Ether derivatives are&nbsp;due to expire on Friday.
Meanwhile, Bitcoin Thursday during pre-market hours was trading at $95,621.41. The cryptocurrency briefly hit an intraday peak of $99,876.70. A broader cryptocurrency index, which includes tokens such as Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), also experienced a minor recovery, rising by 0.2%.
Why It Matters: MicroStrategy&#8217;s decision to issue more shares comes on the heels of its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42660092/microstrategy-sinks-after-nasdaq-100-inclusion-bitcoin-bet-under-fire">recent inclusion in the Nasdaq 100</a>, which has not been without challenges. The company&#8217;s stock fell over 8.5% on its debut in the index, marking a difficult start to its tenure. Over the past month, MicroStrategy&#8217;s stock has plunged more than 37% from its all-time high, reflecting investor concerns over its aggressive Bitcoin strategy. The company&#8217;s recent sale of $561 million in common stock to purchase an additional 5,262 Bitcoins at an average price of $106,662 per coin has further intensified scrutiny.
The latest analyst ratings for MicroStrategy Inc were issued by Bernstein on Dec.12, and by both TD Cowen and Barclays on Nov. 25. These analysts, <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">tracked by Benzinga</a>, have set an average price target of $546.67, suggesting a potential upside of 58.01% for the stock.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26062848/Screenshot-2024-12-26-at-4.58.41%E2%80%AFPM-1024x364.png" alt="" class="wp-image-707471" /></figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42673114/bitcoins-outperformance-could-leave-dogecoin-shiba-inu-sidelined-but-propel-pepe-dogwifhat-bonk-to-new-highs?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin&#8217;s Outperformance Could Leave Dogecoin, Shiba Inu Sidelined, But Propel Pepe, Dogwifhat, Bonk To New Highs</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

General

$BTC

$DOGE

$ETH

$SOL

MSTR

MicroStrategy Stock Tumbles Over 4% In Thursday Premarket: What's Going On?

Macro Economic Events

Econ #s

Economics

France Jobseekers Total For November 2,935.0K  Vs. 2,891.5K Prior

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and raises the price target from $40 to $42.

Price Target

Analyst Ratings

AVXL

HC Wainwright & Co. Maintains Buy on Anavex Life Sciences, Raises Price Target to $42

Chinese EV startup Nio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) launched its new lower-priced EV brand Onvo in May this year. The brand started selling its first vehicle- the Onvo L60- in late September and since then, Nio sales have been on the rise.
What Happened: The Onvo L60 is a mid-size electric SUV that starts at 206,900 yuan ($28,347) with the battery pack included, much lower than Tesla&#8217;s affordable models Model 3 or Model Y in China.
In September, Nio delivered 832 Onvo L60s despite having only a few selling days. In October, the first full month of sales, Onvo deliveries rose to 4,319. In November, L60 deliveries rose to 5,082, implying demand for the vehicle. 
In August, the month before Onvo deliveries commenced, Nio delivered 20,176 vehicles, marking a growth of just 4.4% year-on-year.
In September, the first month of Onvo L60 deliveries, Nio&#8217;s total deliveries jumped 35.4% as compared to the corresponding period last year. In October and November, deliveries <a href="https://www.benzinga.com/24/12/42260165/li-auto-xpeng-nio-heres-how-november-deliveries-of-chinese-ev-startups-stack-up">marked an increase of 30.5% and 29%</a>, respectively.
Why It Matters: Nio identifies itself as a premium EV brand. Its ET9, for instance, starts at 788,000 yuan, including the battery. 
The low-cost EV from the company&#8217;s Onvo brand has helped it move to the low-cost EV segment which has significant demand.
Earlier this month, Nio also <a href="https://www.benzinga.com/24/12/42550944/whats-going-on-with-nio-stock-today">launched a new brand called Firefly</a>, touted as a rival to Mercedes&#8217; Smart and BMW&#8217;s Mini. The brand&#8217;s first vehicle shares its name and pre-sales started at a price of 148,800 yuan. It is expected to be launched in April 2025.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42668333/tesla-model-x-lucid-gravity-or-rivian-r1s-which-three-row-electric-suv-is-a-better-buy" target="_blank" rel="noreferrer noopener">Tesla Model X, Lucid Gravity Or Rivian R1S: Which Three-Row Electric SUV Is A Better Buy?</a></li>
</ul>
Photo courtesy: Nio

Tech

Nio's Onvo Brand Helps Spur Delivery Growth With Cheaper Offering

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains PolyPid (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy and lowers the price target from $14 to $11.

PYPD

HC Wainwright & Co. Maintains Buy on PolyPid, Lowers Price Target to $11

Raymond James analyst C. Gregory Peters maintains Kemper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMPR#NYSE">KMPR</a>) with a Strong Buy and raises the price target from $75 to $82.

KMPR

Raymond James Maintains Strong Buy on Kemper, Raises Price Target to $82

Earnings

NVNI

Nvni Group Reported FY23 Revenue Growth Of 36% YoY

SATS

Microelectronics Technology Enters Strategic Partnership With EchoStar To Advance Development Of Energy-Efficient Open RAN Macro Radios With NTIA Grant

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) from Neutral to Buy and maintains the price target from $10 to $10.

Upgrades

RAPT

HC Wainwright & Co. Upgrades RAPT Therapeutics to Buy, Maintains Price Target to $10

Demand for <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">artificial intelligence-enabled</a> smartphones could serve as a buffer for parts of the semiconductor industry against a potential slowdown in data center investments, Financial Times <a target="_blank" href="https://www.ft.com/content/54c3d188-9c5d-4664-94c4-366207ef9aad" rel="noreferrer noopener">cites</a> Doug Lefever, CEO of Advantest, a Japanese supplier of chip testing equipment for Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Lefever expressed concern over possible dips in spending by <a target="_blank" href="https://www.benzinga.com/news/24/09/41066968/microsoft-google-meta-pave-path-to-ai-expansion-nvidia-and-broadcom-set-to-reap-benefits" rel="noreferrer noopener">major U.S. tech companies</a>, such as Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), which have been driving the construction of advanced data centers.
Lefever told the FT that while fluctuations in data center spending may not last long, any decline could significantly disrupt the semiconductor supply chain due to its reliance on hyperscalers.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42675098/netflix-takes-vmware-to-court-over-patent-infringement-claims" rel="noreferrer noopener">Broadcom and Netflix Clash Over Patent Disputes Ahead of 2025 Trial</a>
He added that the industry&#8217;s cyclical nature could lead to what he described as &#8220;vicious&#8221; downturns. However, he remained optimistic about the potential growth of AI smartphones, suggesting that a breakthrough application could rapidly drive consumer demand and spark a wave of handset replacements.
Advantest, headquartered in Tokyo, holds over 50% of the semiconductor testing market and has benefited from the rising complexity and cost of chips.
Lefever highlighted the growing complexity of chip testing, with Nvidia&#8217;s latest Blackwell products requiring three to four times longer to test than previous generations, as a key driver of sustained demand for Advantest&#8217;s solutions.
The company&#8217;s success extends to high-end testing equipment, which costs $1 million per unit and boasts a market share exceeding 60% in specific categories. Despite geopolitical challenges, such as U.S. restrictions on China, Lefever told the FT that increased demand elsewhere quickly offset lost sales in China. He emphasized that Advantest remains well-positioned globally, with operations in 18 countries and a diversified customer base.
Apple began introducing its <a target="_blank" href="https://www.benzinga.com/news/24/10/41526650/apples-ai-powered-future-iphone-growth-surge-by-2026-with-new-iphone-17-ai-integration-analyst-says" rel="noreferrer noopener">Apple Intelligence features</a> on October 28 with the launch of iOS 18.1, offering initial AI functionalities.
The rollout will continue with iOS 18.2, including ChatGPT integration and advanced tools like Visual Intelligence and Genmoji, aiming to boost future sales.
Needham&nbsp;analyst Laura Martin expects Apple iPhone to account for up to 96% of the <a target="_blank" href="https://www.benzinga.com/news/24/09/41005053/apple-iphone-to-fuel-96-of-2025-revenue-analyst-says-a-safer-bet-than-ai-heavy-amazon-alphabet-micro" rel="noreferrer noopener">company&#8217;s 2025 revenue</a>.
International Data Corporation (IDC) had <a target="_blank" href="https://www.benzinga.com/news/24/08/40600289/apples-market-share-poised-to-gain-genai-and-iphone-16-lead-the-way-idc" rel="noreferrer noopener">reignited confidence in</a> smartphone manufacturers, including Apple, with a new market forecast projecting a 5.8% rise in global smartphone shipments to 1.23 billion units in 2024, recovering after two tough years.
The report highlighted increased demand for budget Android smartphones in China and emerging markets and strong adoption of generative AI smartphones in premium markets as key growth drivers.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42672262/hive-digital-boosts-ai-ambitions-with-30-million-nvidia-gpu-deployment" target="_blank" rel="noreferrer noopener">HIVE Digital Boosts AI Ambitions With $30 Million Nvidia GPU Deployment</a></li>
</ul>
Image via Shutterstock.

Media

GOOG

GOOGL

MSFT

NVDA

AI Smartphones To Cushion Semiconductor Industry Amid Data Center Uncertainty: Report

This appointment not only introduces strong leadership to Color Star but also strengthens the company's ties with the Middle East, particularly the UAE.

Reported Earlier, Color Star Technology Says Shaikh Humaid Abdulla Rashed Ahmed Almualla, A Prominent Member Of The UAE Royal Family, Has Joined As An Independent Director

HC Wainwright &amp; Co. analyst Andrew Fein initiates coverage on Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) with a Buy rating and announces Price Target of $38.

Initiation

PVLA

HC Wainwright & Co. Initiates Coverage On Palvella Therapeutics with Buy Rating, Announces Price Target of $38

Raymond James analyst C. Gregory Peters downgrades Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) from Market Perform to Underperform.

Downgrades

HGTY

Raymond James Downgrades Hagerty to Underperform

Needham analyst Chris Pierce maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Buy and raises the price target from $26 to $28.

ACVA

Needham Maintains Buy on ACV Auctions, Raises Price Target to $28

Raymond James analyst Aaron Kessler upgrades EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) from Outperform to Strong Buy and maintains the price target from $35 to $35.

EVER

Raymond James Upgrades EverQuote to Strong Buy, Maintains Price Target to $35

Raymond James analyst C. Gregory Peters upgrades Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from Market Perform to Outperform and announces $305 price target.

Raymond James Upgrades Progressive to Outperform, Announces $305 Price Target

Reported Earlier, Nippon Steel Extends Estimated Time To Close US Steel Merger Agreement To Q1 Of Calendar Year 2025 From Previously Expected Q3 Or Q4 Of Calendar Year 2024

Over the next three years, the GDTC plans to continue its expansion, focusing on advancing AI/ML capabilities and developing innovative digital solutions to boost operational efficiency and customer engagement.&nbsp;

Kimberly-Clark Increases Its Commitment To India Through Its Global Digital Technology Center In Bengaluru

In a recent survey conducted by&nbsp;Zoomcar Holdings, Inc. ("Zoomcar" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>), India's leading car-sharing marketplace, reported a remarkable 43% year-on-year growth in bookings for November, driven primarily by a surge in demand during the wedding season. This year's wedding season in India has been the strongest in recent years, emerging as one of the biggest contributors to this growth. With the assumption of a similar growth trend as the upcoming holiday season approaches, Zoomcar recognizes the importance of broadening and diversifying its booking channels to capture greater market potential and has revamped its website booking experience to provide a seamless and user-friendly booking experience, matching the convenience of its mobile app.
 &nbsp;

ZCAR

Zoomcar Reports 43% Booking Surge, Revamps Website Ahead of Holiday Rush

Universal Ibogaine

Discussion surrounding science, industry and psychedelics reform is experiencing an all-time high, and 2024 promises to not only continue but further this trend. 



In 2023, the psychedelics market saw transformative expansion driven by favorable trial outcomes, attracting significant investments that reshaped the industry. Driven by scientific advances and changing perceptions, some recent predictions predict the global market will be worth $7.1 billion by 2032, bringing along increased investor interest.



And yet, as much as the psychedelics industry has huge potential, it is also constrained by ambiguity. The positive path in psychedelics research has not been directly reflected in investments in publicly traded companies in the sphere.



A <a href="https://www.benzinga.com/markets/cannabis/24/02/37070368/groundbreaking-fda-reviews-mdma-therapy-for-ptsd-accepts-new-drug-application">key decision by the FDA</a> concerning MDMA therapy this summer was seen by many as a potential watershed moment either cementing this healthcare sector's legitimacy or reinforcing its uncertain nature.



In this state of affairs, Benzinga is providing a concise recollection of the most significant events in the field through insightful exclusive comments from experts in various specialized areas within the ecosystem.



<h3 class="wp-block-heading">A Look From The UK: The Beckley Ecosystem</h3>



A specialist in psychedelic startup incubation, <a href="https://www.benzinga.com/markets/cannabis/23/10/35452135/ketamine-company-acquisition-alert-beckley-waves-adds-nue-life-to-its-portfolio">Beckley Waves</a> co-founder Rock Feilding-Mellen poses that the most important trend in 2024 will be "a concerted effort and focus" on building infrastructure for psychedelic-assisted therapies (PAT) ahead of the anticipated FDA approval of Lykos Therapeutics' (formerly MAPS PBC) MDMA-assisted therapy by year&#8217;s end.&nbsp;



His view was previewed in a recently announced partnership between Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) and Greenbrook TMS to scale commercial delivery models: "One thing most people still haven&#8217;t recognized is that PAT is a unique treatment that requires not only the psychedelic substance but psychotherapy and specific clinical infrastructure needs that are still rare."



Regarding the evolving legal landscape, Feilding-Mellen views it as "still very much a ‘Wild West'." In this sense, he advises companies seeking to enter this quasi-legal gray area to be cautious about how they position their offerings and the claims they make.&nbsp;



"For example, while several countries allow psychedelic retreats, such as Jamaica, operators can get into trouble by making medical claims about the efficacy of psychedelics in the treatment of PTSD or other mental health issues. This phenomenon has featured prominently in the cannabis market and perhaps even more so in the emerging psychedelic space," Feilding-Mellen said.



The FDA's potential approval of MDMA therapy allowing physicians to prescribe the treatment, Feilding-Mallen says at the state level all eyes will be on Colorado's rollout of its commercial legalization framework. 



"What appears to be opening and a major milestone, is an increase in federal research funding for psychedelic clinical trials. The market opportunities will be those that support clinical trial development, onboarding providers to the PAT paradigm, and enabling safe, legal, and accessible care,' he said.



Neil Markey, co-founder of Jamaica and Netherlands-based <a href="https://www.benzinga.com/markets/cannabis/23/11/35974773/exclusive-beckley-retreats-kicks-off-2024-with-new-program-for-personal-discovery-transformation">Beckley Retreats</a>, sees psychedelics' use will likely evolve into "the betterment of the well.&#8221;&nbsp;



"Use cases will expand beyond clinical application to support mental well-being, creativity, team building. At Beckley Retreats, we have begun to see corporate leaders utilizing psychedelic treatment as a means to personal growth, leading to more adaptable, empathetic business leaders who can foster better communication, teamwork and decision-making. The impacts can improve employee engagement, job satisfaction, and company performance and growth," Markey says.&nbsp;



A key challenge the space will face this year: "Wounded healers or practitioners who are drawn to psychedelic treatment but have not done enough of their own personal work and healing," Markey said. Also, alternative energy medicines including reiki and grounding are expected to grow in popularity in 2024.&nbsp;



John Yoo, CEO of <a href="https://www.benzinga.com/markets/cannabis/24/02/37394447/beckley-academys-open-source-psychedelic-therapy-learning-framework-is-out-whats-it-all-about-au">Beckley Academy</a>, spoke on the clinician training that will be necessary for psychedelic therapies to scale.&nbsp;



"We are in a state of transition, so everything that happens related to psychedelic use (medical or not) will draw attention and scrutiny. Safety and efficacy will continue to be studied and analyzed as treatments, like MDMA-assisted therapy, move from a clinical trial model to health care. Standards around dosing and practice will be introduced for ketamine-assisted therapy. Telehealth KAT practices may come under additional regulation or scrutiny as more people seek accessible treatment."



Yoo says the team also expects to see an increased emphasis on harm reduction education versus a &#8220;just say no&#8221; approach toward promoting a better understanding and safer access to psychedelics.



"From the lens of educators, we see a tension between offering high-quality education -which gives practitioners enough time, depth, skills practice and supervision- and making training affordable and efficient so that the field can meet the demand for PAT," Yoo added. "Less-experienced therapists coming to this work earlier in their careers will need ample experiential training, mentorship and supervision to safely and ethically sit with clients."&nbsp;



He foresees a shift towards MDMA-assisted therapy training, although it's still unclear which organizations will be able to certify therapists.



<h3 class="wp-block-heading">Ketamine Specialty Meets MDMA</h3>



Charles Patti is CEO of Florida-based ketamine clinic MY Self Wellness, co-founder of nonprofit Warriors of Consciousness and an advocate for mental health and psychedelic medicine as his personal healing story for overcoming addiction involves the use of psilocybin mushrooms, DMT and ketamine.



Expected FDA approval for MDMA therapy will likely impact all areas of psychedelic medicine, including existing ketamine clinics. As such, MY Self Wellness is getting ready to provide joint ketamine and MDMA therapy as a treatment offering for PTSD.



"It will be a great addition to our ketamine services. Ketamine and MDMA are like peanut butter and jelly. MDMA is a ‘heart opener' and may be very beneficial for talk therapy. It can be used to talk through one's traumatic experiences, while ketamine is more of a deeper dive psychedelic experience," says Patti.&nbsp;



The clinic recently partnered with several veteran community organizations to offer psychedelic treatment (for the moment solely ketamine) to this population. 



In Patti's words, "Veterans or those with PTSD can get to the root cause of what's making them suffer by using these two healing therapies therapeutically," to be provided in separate days.



He sees the veteran community is helping break the negative stigma tied to psychedelic therapy to treat mental health conditions.&nbsp;



"People listen to veterans because they have served our country and don't want them to suffer. Before, the government would have never approved psychedelics' use for mental health purposes. However, due to what it's doing with our veteran and first responder community, there has been more of a positive narrative."&nbsp;



Further, he sees celebrities going public with their psychedelic use stories, as well as increasing data being collected with clinical studies conducted by major institutions like MAPS, Johns Hopkins and Imperial College London, the taboo reputation is turning more positive and doubts on the efficacy of the medicine are going away.&nbsp;



"The expected impact of the direction of psychedelic treatment will be similar to those who tried to penetrate the ketamine industry. Many individuals will fail to come into the market, because they are trying to make a quick return on their investment. Those who are passionate about psychedelics and helping others will play the long game by waiting for the laws to pass and eventually be successful in their endeavors. With the intention to prevent inexperienced companies from just opening up shop once the FDA approves MDMA, it has been speculated that the law may require clinics to have been open for over a couple of years in order to integrate MDMA therapy," says Patti.



Even though the underground market will "always exist" as "illegal use is tantalizing because people want what they can't have", Patti says he&#8217;s certain that the normalization of psychedelics will shift the entire mental health paradigm. 



"People are going to visually see something that really works and are not going to be able to say it's illegal anymore. It will shift these long-term psychedelic healing modalities to become more mainstream. As a result, people will stop relying on pills and multiple medications every day. 20 years from now, Xanax and antidepressants may become a thing of the past and psychedelic medicine will be the new standard."



<h3 class="wp-block-heading">Expert Investor's Take</h3>



Known by some as "the psychedelic concierge to the stars,&#8221; Zappy Zapolin is a prominent figure in the field and a longtime trendspotter in many industries. <a href="https://www.benzinga.com/general/biotech/24/02/37397999/podcast-post-frenzy-psychedelics-investing-and-reclaiming-the-right-to-pursue-happiness-with-zapp">Among his many hats</a>, he currently advises companies in the psychedelic sector including Psycheceutical Bioscience (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BWVI#OTC">BWVI</a>) (currently conducting clinical trials in Australia for a topical ketamine delivery for PTSD treatment) and Canada-based Universal Ibogaine (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IBOGF#OTC">IBOGF</a>).



Reflecting on three decades of market experiences, Zapolin sees parallels between historical market bubbles, such as the Wall Street crash and the rise of the internet bubble, all sharing a recurring pattern: quality emergence post-bubble burst. 



In this sense, he sees the psychedelics industry is at a great moment "where the hype is gone, but the really good science and some very recent indicators of companies getting large funding in this space remain.&#8221;



During the internet bubble, Zapolin seized opportunities by purchasing domain names at low prices. He views a similar trend in the psychedelics market, although he does emphasize on the need to identify quality companies, with enough (and influential) funding and expertise to perform successful R&amp;D and provide long-term gains. &#8220;You start in the beginning of a trillion-dollar industry, and one or two of your several quality investments work out.&#8221;



His investments in the sector follow mentor Mike Milken's advice on the importance of intellectual property for value creation. And then, "wealth is the byproduct.&#8221; 



As much as he is a firm believer in psychedelics as healing modalities, Zapolin is particularly pumped about ibogaine's therapeutic benefits for addiction treatment, and has joined Lamar Odom to create awareness on the substance's vast potential. "Ibogaine's work is like a full reset -mental, physical, wiping your prefrontal cortex so you don&#8217;t have cravings."



Photo by <a href="https://unsplash.com/@cristian1?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Cristian Escobar</a> on <a href="https://unsplash.com/photos/person-holding-lighted-sparklers-abkEAOjnY0s?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a>.

Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More

Comments

Universal Ibogaine

News

Latest news for Universal Ibogaine (OTC:IBOGF) Stock

Wednesday, March 06, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga